New study aims to cut drug side effects for stomach cancer patients
NCT ID NCT05493215
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether regularly checking imatinib levels in the blood can reduce side effects and improve quality of life for people with gastrointestinal stromal tumors (GIST). About 28 adults starting or recently starting imatinib will participate. The goal is to see if this monitoring approach lowers severe side effects while keeping the drug at effective levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Markey Cancer Center
RECRUITINGLexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Study aims to pinpoint ideal imatinib dose for GIST patients
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New hope for rare stomach cancer: chemo drug shows promise in early trial
- New oral paclitaxel trial offers hope for Hard-to-Treat GIST